|Day Low/High||70.37 / 73.40|
|52 Wk Low/High||59.60 / 88.87|
With China based customers doubling in 2017, Medidata (NASDAQ: MDSO) announced the appointment of Jim (Hui) Xu as general manager in the market, and plans to double the size of local talent.
To make clinical research truly patient-centric, Medidata (NASDAQ: MDSO) announced the launch of the Patient Burden Index (PBI) on the Medidata Cloud, the Intelligent Platform for Life Sciences.
Medidata (NASDAQ:MDSO) today announced that it has entered into a definitive agreement to acquire SHYFT Analytics, bringing the leading platform for clinical development together with the leading platform for commercial and real-world data analytics.
Medidata (NASDAQ: MDSO) announced that Memorial Sloan Kettering Cancer Center (MSK) is using Rave Omics with Biomarker Discovery for patients with pancreatic cancer, an example of the paradigm shift in clinical trials through the systematic capture of...
For the second consecutive year, Medidata (NASDAQ:MDSO) will be presenting its pioneering analytics innovation during the 2018 ASCO Annual Meeting.
Biotech company, PhaseBio Pharmaceuticals, has become Medidata's (NASDAQ:MDSO) 1,000th customer.
Heart disease is the leading cause of death for both men and women. In partnership with the American Heart Association, Medidata (NASDAQ:MDSO) is holding its first annual 'Global Heart Health Awareness' week to provide employees around the world with...
Medidata (NASDAQ:MDSO) today announced that Tarek Sherif, chairman and chief executive officer, will present at the 46th Annual J.
To help organizations mitigate the risk of regulatory non-approval and delays, Medidata Solutions (NASDAQ:MDSO) is transforming how clinical trial data is validated prior to FDA submission with Edge Trial Assurance.
Medidata (NASDAQ: MDSO) is pleased to announce that its director of strategic accounts and medical device/diagnostic sales, Melinda Pautsch, has been named a 2018 "Rising Star" by the Healthcare Businesswomen's Association (HBA).
Medidata (NASDAQ: MDSO) today announced that Rouven Bergmann, chief financial officer, will present at the Jefferies 2018 Global Technology Conference on Wednesday, May 9, 2018, at 2:30 p.
Medidata (NASDAQ:MDSO) today announced that Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), expanded its use of the Medidata Clinical Cloud® to automate operations, increase efficiencies, and gain better data visibility in order to accelerate their 2125...
Medidata (NASDAQ: MDSO) is pleased to announce that its risk based monitoring solution, Edge Strategic Monitoring, won an Informa Clinical and Research Excellence (CARE) Award, marking the third consecutive year the company earned this distinction.
Medidata (NASDAQ: MDSO) is hosting the final European NEXT conference in London this week, with executives presenting from Novartis, aparito, and the global life sciences community.
Medidata (NASDAQ:MDSO) today announced its financial results for the first quarter of 2018.
Medidata (NASDAQ:MDSO), the leading global provider of cloud-based technology and data analytics for clinical research, today announced that it will release its first quarter 2018 financial results before the open of the...
Medidata (NASDAQ: MDSO) announced that the National Health and Medical Research Council Clinical Trial Centre (NHMRC CTC), University of Sydney, will now use Medidata's unified platform and analytics for all major new...
Software stocks have been on fire for several quarters. Now, they could be a overdue for a pullback right along with the FAANG names.
Medidata (NASDAQ:MDSO) successfully hosted NEXT conferences in Basel and Frankfurt, with executives from global life sciences and pharmaceutical companies presenting, including Bayer, Cancer Research UK, and Roche.
Oncology is leading the precision medicine revolution, as clinical researchers leverage and identify biomarkers to target patient subsets with more effective treatments, and the promise of improving Phase I success rate...
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACIW, AMC, CTRP, GSIT, ITGR, JNP, KFFB, MD, MDSO, NJR, VECO Downgrades: NEM, TFX, TTEC Initiations: CNAT, OTEL Read on to get TheStreet Quant Ratings' detailed report:
Medidata (NASDAQ:MDSO) today announced that Tarek Sherif, chief executive officer, and Rouven Bergmann, chief financial officer, will present at the Morgan Stanley Technology, Media & Telecom Conference on Wednesday,...
Santen Pharmaceutical Co., Ltd, is expanding its use of the Medidata Clinical Cloud® with the adoption of Edge CTMS (Clinical Trial Management System) to support its clinical trial operations, in...
Medidata (NASDAQ: MDSO) today announced that eClinical Solutions LLC, an industry-leading provider of end-to-end data management services and cloud based products for clinical data optimization, is expanding their...
Medidata (NASDAQ:MDSO) has been named to Barron's first annual list of the " 100 Most Sustainable Companies" in the U.
Aperio, a leading clinical research organization (CRO) formerly known as iNNO Clinical Outcomes, has expanded its use of the Medidata Clinical Cloud ® platform to include Edge eTMF and Edge CTMS, Medidata...
As clinical trials become more complex, sponsors and contract research organizations (CROs) are looking for a unified platform to help them overcome challenges such as dealing with disparate systems, complying with new...
Medidata (NASDAQ:MDSO) announced today that its virtual trials platform, Engage, is now being offered as a part of the Medidata Clinical Cloud®, providing researchers unmatched flexibility to conduct clinical trials...
Medidata (NASDAQ:MDSO) today announced its financial results for the fourth quarter and full year 2017 and provided detailed financial guidance for the full year 2018.
Targeted therapies create new opportunities for patients, but can require complex trial design to achieve their promise.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.